Daré Bioscience (DARE) Stock Price, News & Analysis

Company Overview

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: $2.89 to $2.92
• 50-Day Range: $2.88 to $3.18
• 52-Week Range: $2.67 to $7.56
• Volume: 5,764 shs
• Average Volume: 45,677 shs
• Market Capitalization: $25.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Moderate Buy

Daré Bioscience Stock Analysis - MarketRank™

Daré Bioscience scored higher than 44% of companies evaluated by MarketBeat, and ranked 805th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Daré Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Daré Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Daré Bioscience are expected to decrease in the coming year, from ($0.49) to ($1.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Daré Bioscience is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Daré Bioscience is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.72% of the float of Daré Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Daré Bioscience has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daré Bioscience has recently decreased by 28.60%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Daré Bioscience does not currently pay a dividend.

Dividend Growth

Daré Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.72% of the float of Daré Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Daré Bioscience has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daré Bioscience has recently decreased by 28.60%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.43

News Sentiment

Daré Bioscience has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Daré Bioscience this week, compared to 1 article on an average week.

MarketBeat Follows

Only 2 people have added Daré Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Daré Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.00% of the stock of Daré Bioscience is held by insiders.

Percentage Held by Institutions

Only 6.70% of the stock of Daré Bioscience is held by institutions.

DARE Stock Analysis - Frequently Asked Questions

How have DARE shares performed this year?

Daré Bioscience's stock was trading at $3.12 at the start of the year. Since then, DARE stock has decreased by 7.1% and is now trading at $2.90.
View the best growth stocks for 2025 here.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) issued its quarterly earnings results on Monday, March, 31st. The biotechnology company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.02. The biotechnology company earned ($0.06) million during the quarter, compared to the consensus estimate of $1 million.
Read the conference call transcript.

When did Daré Bioscience's stock split?

Shares of Daré Bioscience reverse split on Monday, July 1st 2024. The 1-12 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Daré Bioscience?

Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Daré Bioscience investors own include FuelCell Energy (FCEL), Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Vaxart (VXRT), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 3/31/2025
• Today: 4/17/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DARE
• CIK: 1401914
• Web: www.darebioscience.com
• Phone: (858) 926-7655
• Fax: 617-494-1544
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.00
• High Stock Price Target: $36.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +727.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-30,160,000.00
• Net Margins: -191.65%
• Pretax Margin: -191.60%
• Return on Equity: N/A
• Return on Assets: -18.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.14
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: $9,784.00
• Price / Sales: 2,623.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.61) per share
• Price / Book: -4.75

Miscellaneous

• Outstanding Shares: 8,850,000
• Free Float: 8,352,000
• Market Cap: $25.67 million
• Optionable: Not Optionable
• Beta: 1.34